UK Bans Puberty Blockers for Gender Dysphoria Citing Safety Concerns

The decision follows a review by Baroness Cass, who criticized misinformation and highlighted risks associated with the drugs.

Health Secretary Wes Streeting announced an indefinite ban on puberty blockers for children seeking gender transition, citing safety risks identified by medical experts.
Baroness Hilary Cass, author of a landmark review, emphasized that the ban is based on scientific evidence and safety concerns, not discrimination.
The drugs, previously used off-label for gender dysphoria, will only be available through NHS clinical trials and remain approved for early-onset puberty and some cancer treatments.
Critics, including Labour and Green MPs, argue the ban could harm transgender youth, but Cass refuted claims that denying puberty blockers leads to increased suicide risk.
The NHS is expanding mental health support for affected youth, with Cass advocating for holistic and multidisciplinary care instead of a one-size-fits-all approach.